$SLNO preliminary Q4 Vykat sales $90-92M vs $86M Visible Alpha consensus. That's somewhat of a relief. Good #JPM26 Monday morning to you all!
$SLNO is repurchasing $100M of its stock. Strong move. https://t.co/urev6a6Cqn
$SLNO has a lot of work to do. Management has not handled this situation well at all. @ScorpionFund is right about the call last night. It was terrible. If Kir is wrong about Vykat, then Soleno needs to prove it. More offense, less defense.
My unsolicited advice to $SLNO would be: More offense, less defense. Q3 was good. $66M in sales, 397 new start forms (higher than Q2), discontinuation rate higher but within expected range. If @ScorpionFund is disrupting the launch, like Soleno claims, fight that fight, but no need to do it publicly.
@bigpharmaguy As a $SLNO shareholder, I wouldn't want Anish to be Doug Ingram, but maybe a little teeny bit sprinkled in?
I can't remember the last time that a short seller factored so heavily in a biotech earnings call like this $SLNO call. Maybe $MDXG back when Marc Cohodes was waging his war. @ScorpionFund is in Soleno's collective heads.
On call, $SLNO said Vykat discontinuation rate was 8% at end of Q3, and has been 10% overall. "While the discontinuation rate has increased, it remains below our expected long term rate based on autical cloud data."
$SLNO results look solid, stock down. Tell me why?
$SLNO Vyktat XR sales $66M
@CoinbasedBTC I've been very bullish on $SLNO. Let's hope that continues.
$SLNO earnings tonight. Consensus Vykat XR sales $54M, but buyside whisper is $60-70M. Details on discontinuation rate also important.
@BiotechPort I didn't invent the expectation of $SLNO pre-announcing Q3 sales. I'm merely telling you 1/ it existed; and 2/ it's not happening.
$SLNO did not preannounce Q3 sales. That's disappointing, as much as disclosure of preliminary Vykat XR sales for Q3 was a possibility to counter the bear thesis. Looks like we need to wait for the scheduled earnings report on Nov. 4.
This week's Biotech scorecard newsletter: (Almost) 100% positive vibes 1. $QURE, of course. The 75% slowing of disease progression reported by Uniqure with its Huntington’s disease gene therapy AMT-130 was the kind of stop-reading-and-gasp moment that crystalizes the profound impact these types of one-time treatments can have for patients dealing with rare diseases. But, bear in mind... The validity of external control arms like the one used by Uniqure is still hotly debated, even as regulators, including the FDA, allow them under certain circumstances. It’s been lost to memory, but recall that the AMT-130 study started with a true, sham-surgery control arm that showed no benefit for the gene therapy. It was only after the company reconfigured the study and started using natural history comparators was a benefit observed. Also: -- Why $STOK 's quiet move higher makes sense. The stock is up almost four-fold from its April low and has doubled year to date. Why? I asked around... -- $ACAD was a "clearing event" for $SLNO. Next up, earnings. What's the whisper number for Vykat sales? Newsletter link below...
Acadia Pharma $ACAD drug for Prader-Willi syndrome fails late-stage study In reaction, $SLNO higher https://t.co/OLXtLcVBy5
I asked a $SLNO shareholder: WTF is going on? Their reply: "PTSD from Sarepta" 🎯
$SLNO under $50, cut in half since @ScorpionFund went public with his short thesis. I still think Kir will be wrong fundamentally, but for now, he's most definitely winning. Hat. Tip.
$SLNO v @ScorpionFund update: Baird analyst @BrianSkorney spoke with Prader-Willi expert Dr. Ashley Shoemaker. https://t.co/Jjf4NISLIm
My other story today: $SLNO vs @ScorpionFund I spoke with CEO Anish Bhatnagar about Kir Kahlon's short report that claims Prader-Willi patients on Vykat XR are "dropping like flies." They're not. Still, post-marketing safety surveillance is important. https://t.co/hu7Zx6YUjo
